The therapeutic community is abuzz with anticipation surrounding retatrutide, a new dual GIP and GLP-1 agonist that’s showing significant potential in clinical trials for addressing obesity. Unlike some current weight loss solutions, retatrutide appears to provide a greater substantial decrease i